Business
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease Anticipate topline results in late 2026 Topline results from the Phase 1 study investigating a subcutaneous sabirnetug formulation support further development of this dosing option for patientsCash, cash equivalents and marketable securities of $231.5 million as of Dec. 31, 2024, expected to support current clinical and operational activities into the first half
About this update from Acumen Pharmaceuticals, Inc.
[{"type":"image","alt":"Acumen Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Acumen Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5J.4IvnfhFM_bTHIo4TE3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879","width":300,"height":62}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment complete for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease","length":134,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Anticipate topline results in late 2026","length":39,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":39,"olType":false}]},{"val":[{"type":"text","content":"Topline results from the Phase 1 study investigating a subcutaneous sabirnetug formulation support further development of this dosing option for patients","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $231.5 million as of Dec. 31, 2024, expected to support current clinical and operational activities into the first half of 2027","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to host conference call and webcast today at 8:00 a.m. ET ","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":570,"olType":false},{"type":"text","content":"NEWTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the full year ended December 31, 2024 and provided a business update.","length":407,"tagName":"p"},{"type":"text","content":"“I am exceptionally proud of the considerable progress our team has made this past year in advancing the clinical development of sabirnetug, our next generation treatment for early Alzheimer’s disease. We completed enrollment in our 540-participant Phase 2 study, ALTITUDE-AD, ear...